Procyon Research Ltd
Procyon Research Ltd is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Procyon Research Ltd.
Procyon Research Ltd is a company.
Key people at Procyon Research Ltd.
Key people at Procyon Research Ltd.
Procyon Research Ltd (now operating as Procyon Diagnostics or Procyon Dx) is a UK-based biotech startup spun out from Queen Mary University of London (QMUL) in 2025, focused on developing biomarker technologies for early-stage cancer detection.[1] The company builds precision diagnostic assays using advanced biomarkers, algorithmic, and machine learning analysis on non-invasive body fluids like blood and urine, targeting markets in Europe, North America, and the Middle East; its first product, the PancRISK test for pancreatic cancer risk, is planned for launch in early 2026.[1][6] Procyon serves healthcare providers, patients at high risk for pancreatic cancer, and researchers, addressing the critical problem of detecting pancreatic cancer at an early, treatable stage when current methods often fail due to late diagnosis; early momentum includes securing a QMUL license in October 2025, closing pre-seed funding, and initial team hires by November 2025.[1]
(Note: Search results also reference a defunct 1982 British firm, Procyon Research Ltd, which provided scientific computing hardware/software and is no longer active,[3][4][5] and a separate US investment firm, Procyon Partners.[2] This analysis focuses on the active biotech entity matching the query most closely based on recency and relevance.[1])
Procyon Dx emerged in April 2025 as a spin-out from QMUL to commercialize clinical biomarker research, particularly the PancRISK test invented by Professor Tatjana Crnogorac-Jurcevic.[1] The leadership team includes Dr. Anthony Cooke as CEO, with 5+ years introducing global early-detection cancer tests to the UK private market and NHS, and a history with startups; and Clive Minihan as Chairman, with 30 years scaling tech startups in the UK/US, driving 5 exits worth over £200 million to firms like Becton Dickinson, Thermo Fisher, and Siemens.[1] Key milestones: QMUL license obtained and pre-seed funding closed in October 2025, followed by first hires in November 2025, building on academic R&D for non-invasive pancreatic cancer detection via urine samples.[1][6]
Procyon rides the precision oncology and liquid biopsy wave, where non-invasive tests address pancreatic cancer's dismal 10-12% 5-year survival rate due to late detection, amid surging demand for AI-enhanced biomarkers.[1][6] Timing is ideal post-2025 spin-out, aligning with global pushes for early cancer screening (e.g., NHS goals) and VC interest in diagnostics; market forces like aging populations, rising cancer incidence, and tech advances in ML favor scalable urine/blood assays over invasive biopsies.[1] By commercializing university IP, Procyon influences the UK/EU biotech ecosystem, bridging academia to clinics and potentially setting standards for multi-cancer panels.
Procyon is poised for 2026 PancRISK launch, targeting UK NHS/private adoption then global expansion, with data from initial tests accelerating a broader cancer detection portfolio.[1] Trends like AI diagnostics integration and regulatory fast-tracks for high-need cancers (e.g., pancreatic) will propel growth, potentially drawing Series A funding via proven leadership exits. Its influence could evolve from niche startup to ecosystem leader in liquid biopsies, humanizing early detection and amplifying QMUL's impact—positioning it as a vital player in beating cancer's deadliest forms.